These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9163995)

  • 21. Japan: are statins still good for everybody?
    Sirtori CR; Calabresi L
    Lancet; 2006 Sep; 368(9542):1135-6. PubMed ID: 17011926
    [No Abstract]   [Full Text] [Related]  

  • 22. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients.
    Castaño G; Más R; Arruzazabala ML; Noa M; Illnait J; Fernández JC; Molina V; Menéndez A
    Int J Clin Pharmacol Res; 1999; 19(4):105-16. PubMed ID: 10939028
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pravastatin multicenter clinical trial in patients with hypercholesterolemia and multiple risk factors].
    Barrett e Pesquisadores AC
    Arq Bras Cardiol; 1997 Jan; 68(1):65-71. PubMed ID: 9334463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A need to redefine the consensus on the use of statins in coronary heart disease prevention.
    Fruchart JC
    Eur Heart J; 2000 Oct; 21(19):1572-3. PubMed ID: 10988008
    [No Abstract]   [Full Text] [Related]  

  • 25. A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women.
    Davidson MH; Testolin LM; Maki KC; von Duvillard S; Drennan KB
    Arch Intern Med; 1997 Jun; 157(11):1186-92. PubMed ID: 9183229
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Coronary heart disease: grave deficiencies in secondary prevention. Almost no one is concerned with blood lipids].
    Arnheim K
    MMW Fortschr Med; 2000 Jun; 142(24):18. PubMed ID: 10895577
    [No Abstract]   [Full Text] [Related]  

  • 27. [Primary and secondary prevention of coronary disease by statins].
    Ferrières J
    Ann Cardiol Angeiol (Paris); 1999 Feb; 48(2):128-36. PubMed ID: 12555337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Updated guidelines support even lower cholesterol levels for at-risk patients.
    Levenson D
    Rep Med Guidel Outcomes Res; 2004 Aug; 15(15):1, 6-7. PubMed ID: 15320342
    [No Abstract]   [Full Text] [Related]  

  • 29. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients.
    Strony J; Hoffman R; Hanson M; Veltri E
    Clin Ther; 2008 Dec; 30(12):2280-97. PubMed ID: 19167588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Congress information. Clinical benefits of the use of a statin following myocardial infarction in patients without frank hypercholesterolemia].
    Kulbertus H
    Rev Med Liege; 1996 Oct; 51(10):668-9. PubMed ID: 8984565
    [No Abstract]   [Full Text] [Related]  

  • 32. The effect of pravastatin on coronary events after myocardial infarction.
    Auerbach I; Behar S; Motro M
    N Engl J Med; 1997 Mar; 336(13):962. PubMed ID: 9072702
    [No Abstract]   [Full Text] [Related]  

  • 33. How common is rhabdomyolysis in patients receiving lipid-lowering therapy?
    Phillips PS
    Nat Clin Pract Cardiovasc Med; 2005 Mar; 2(3):130-1. PubMed ID: 16265453
    [No Abstract]   [Full Text] [Related]  

  • 34. [Use of statins in primary prevention: from the theoretical presuppositions to complex scenarios of the real world].
    Poli A; Menotti A
    G Ital Cardiol; 1999 Oct; 29(10):1123-30. PubMed ID: 10546121
    [No Abstract]   [Full Text] [Related]  

  • 35. Economic benefit analysis of primary prevention with pravastatin. Modelling economic benefits after such long term treatment is inappropriate.
    Pharoah P
    BMJ; 1998 Apr; 316(7139):1241-2. PubMed ID: 9553009
    [No Abstract]   [Full Text] [Related]  

  • 36. [Consensus conference. Short text. Hepatitis C: screening and treatment. Association Française pour l'étude du Foie Société Nationale Française de Gastro-Entérologie et Association Française de Chirurgie Hépato-Biliaire et de Transplantation. Groupe Française d'etude Moléculaire des Hépatites. Club d'Histopathologie Digestive et Hépatique. Société Française d'Immunologie. Société Nationale Française de Médecine Interne. Société Française de Microbiologie].
    Gastroenterol Clin Biol; 1997; 21(1):45-9. PubMed ID: 9091390
    [No Abstract]   [Full Text] [Related]  

  • 37. Smoking cessation as a rigorous primary intervention for coronary events in middle-aged men. A commentary based on the WOSCOP findings. West of Scotland Coronary Prevention Study.
    von Eyben FE
    Eur Heart J; 1997 Jul; 18(7):1187-9. PubMed ID: 9243155
    [No Abstract]   [Full Text] [Related]  

  • 38. Hyperlipidaemia and cardiovascular disease.
    Wright R; Northridge D
    Curr Opin Lipidol; 1996 Jun; 7(3):U92-8. PubMed ID: 8818521
    [No Abstract]   [Full Text] [Related]  

  • 39. Therapy and clinical trials.
    Sussekov AV
    Curr Opin Lipidol; 1997 Oct; 8(5):U73-5. PubMed ID: 9335964
    [No Abstract]   [Full Text] [Related]  

  • 40. [The drug therapy of hypercholesterolemia].
    Berthold HK; von Bergmann K
    Dtsch Med Wochenschr; 1996 May; 121(22):729-34. PubMed ID: 8646985
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.